R. Riisbro

发表

Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.

N. Brünner, A. Harris, I. Christensen, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera

N. Brünner, R. Riisbro, M. Jensen, 2002, European journal of haematology.

Monoclonal antibody TB-403: a first-in-human, Phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects.

R. Riisbro, J. Stassen, S. Pakola, 2011, Clinical therapeutics.

High Serum YKL-40 Levels in Patients with Primary Breast Cancer is Related to Short Recurrence Free Survival

N. Brünner, A. Harris, I. Christensen, 2003, Breast Cancer Research and Treatment.

Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.

H. Nielsen, I. Christensen, R. Riisbro, 2005, The International journal of biological markers.

Preoperative Plasma Soluble Urokinase Plasminogen Activator Receptor as a Prognostic Marker in Rectal Cancer Patients. An Eortc-Receptor and Biomarker Group Collaboration

H. Nielsen, N. Brünner, I. Christensen, 2005, The International journal of biological markers.

Soluble urokinase plasminogen activator receptor in blood transfusion components

H. Nielsen, N. Brünner, I. Christensen, 2004, Transfusion medicine.

Soluble Urokinase Plasminogen Activator Receptor Measurements: Influence of Sample Handling

N. Brünner, I. Christensen, R. Riisbro, 2001, The International journal of biological markers.

A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer

N. Brünner, J. Overgaard, J. Alsner, 2008, Acta oncologica.

Elevated plasma levels of TIMP‐1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders

N. Brünner, L. Kjeldsen, R. Riisbro, 2003, European journal of haematology.

Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma‐soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism

N. Brünner, R. Riisbro, M. Jensen, 2003, European journal of haematology.

Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC)

I. Christensen, R. Riisbro, S. Engelholm, 2006, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.

N. Brünner, C. Sweep, E. McDermott, 2005, Oncology reports.

Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.

H. Nielsen, N. Brünner, I. Christensen, 2001, Gynecologic oncology.

Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer

N. Brünner, J. Overgaard, R. Riisbro, 2007, Acta oncologica.